These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 15735050)

  • 1. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands.
    Hershberger PA; Vasquez AC; Kanterewicz B; Land S; Siegfried JM; Nichols M
    Cancer Res; 2005 Feb; 65(4):1598-605. PubMed ID: 15735050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen.
    Stabile LP; Davis AL; Gubish CT; Hopkins TM; Luketich JD; Christie N; Finkelstein S; Siegfried JM
    Cancer Res; 2002 Apr; 62(7):2141-50. PubMed ID: 11929836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
    Stabile LP; Lyker JS; Gubish CT; Zhang W; Grandis JR; Siegfried JM
    Cancer Res; 2005 Feb; 65(4):1459-70. PubMed ID: 15735034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of coregulators influenced by estrogen receptor subtype specific binding of the ER antagonists 4-hydroxytamoxifen and fulvestrant.
    Evers NM; Wang S; van den Berg JH; Houtman R; Melchers D; de Haan LH; Ederveen AG; Groten JP; Rietjens IM
    Chem Biol Interact; 2014 Sep; 220():222-30. PubMed ID: 25014417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.
    Siegfried JM; Farooqui M; Rothenberger NJ; Dacic S; Stabile LP
    Oncotarget; 2017 Apr; 8(15):24063-24076. PubMed ID: 28445992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V; Gougelet A; Maillard S; Renoir JM
    Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
    Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
    J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer.
    Garon EB; Pietras RJ; Finn RS; Kamranpour N; Pitts S; Márquez-Garbán DC; Desai AJ; Dering J; Hosmer W; von Euw EM; Dubinett SM; Slamon DJ
    J Thorac Oncol; 2013 Mar; 8(3):270-8. PubMed ID: 23399957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta.
    Kumar A; Klinge CM; Goldstein RE
    Int J Oncol; 2010 May; 36(5):1067-80. PubMed ID: 20372779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells.
    Dougherty SM; Mazhawidza W; Bohn AR; Robinson KA; Mattingly KA; Blankenship KA; Huff MO; McGregor WG; Klinge CM
    Endocr Relat Cancer; 2006 Mar; 13(1):113-34. PubMed ID: 16601283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells.
    Hershberger PA; Stabile LP; Kanterewicz B; Rothstein ME; Gubish CT; Land S; Shuai Y; Siegfried JM; Nichols M
    J Steroid Biochem Mol Biol; 2009 Aug; 116(1-2):102-9. PubMed ID: 19460433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) alpha and ERbeta.
    Routledge EJ; White R; Parker MG; Sumpter JP
    J Biol Chem; 2000 Nov; 275(46):35986-93. PubMed ID: 10964929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporally distinct and ligand-specific recruitment of nuclear receptor-interacting peptides and cofactors to subnuclear domains containing the estrogen receptor.
    Schaufele F; Chang CY; Liu W; Baxter JD; Nordeen SK; Wan Y; Day RN; McDonnell DP
    Mol Endocrinol; 2000 Dec; 14(12):2024-39. PubMed ID: 11117532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains.
    Dutertre M; Smith CL
    Mol Endocrinol; 2003 Jul; 17(7):1296-314. PubMed ID: 12714702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma.
    Niikawa H; Suzuki T; Miki Y; Suzuki S; Nagasaki S; Akahira J; Honma S; Evans DB; Hayashi S; Kondo T; Sasano H
    Clin Cancer Res; 2008 Jul; 14(14):4417-26. PubMed ID: 18579664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. G protein-coupled estrogen receptor (GPER) mediates NSCLC progression induced by 17β-estradiol (E2) and selective agonist G1.
    Liu C; Liao Y; Fan S; Tang H; Jiang Z; Zhou B; Xiong J; Zhou S; Zou M; Wang J
    Med Oncol; 2015 Apr; 32(4):104. PubMed ID: 25744245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.
    Siegfried JM; Gubish CT; Rothstein ME; Henry C; Stabile LP
    J Thorac Oncol; 2012 Mar; 7(3):485-95. PubMed ID: 22258476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor.
    Gee AC; Carlson KE; Martini PG; Katzenellenbogen BS; Katzenellenbogen JA
    Mol Endocrinol; 1999 Nov; 13(11):1912-23. PubMed ID: 10551784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptors, antiestrogens, and non-small cell lung cancer.
    Bogush TA; Dudko EA; Beme AA; Bogush EA; Kim AI; Polotsky BE; Tjuljandin SA; Davydov MI
    Biochemistry (Mosc); 2010 Dec; 75(12):1421-7. PubMed ID: 21314611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.
    Reiter R; Oh AS; Wellstein A; Riegel AT
    Oncogene; 2004 Jan; 23(2):403-9. PubMed ID: 14691461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.